{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-24-000165","form_type":"8-K/A","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.504311+00:00","generated_at":"2026-05-31T11:38:30.219156+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Pacific Biosciences estimates $27M in charges for expense reduction plan; San Diego office closure","bullets":["Total charges estimated at $27M in fiscal 2024, including $10M compensation, $12M lease costs, $4M inventory.","Cash expenses of ~$21M: $10M severance and benefits, $11M San Diego office closure and lease costs.","Substantially all charges expected in Q2 and Q3 2024; company had previously disclosed plan on April 16, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-24-000165","json":"https://secwatch.observer/filing/0001299130-24-000165.json","markdown":"https://secwatch.observer/filing/0001299130-24-000165.md","text":"https://secwatch.observer/filing/0001299130-24-000165.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000165/0001299130-24-000165-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913024000165/pacb-20240416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:38:30.219156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}